Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Allergy Other
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Allergy Other
    Inhaled Ciclesonide Improves Asthma Control: Presented at ACAAI - (DGDispatch)
    Efficacy of Aqueous Triamcinolone Acetonide in Allergic Rhinitis Not Affected by Gender: Presented at ACAAI - (DGDispatch)
    FDA Approves a C1-Esterase Inhibitor for Abdominal Attacks, Facial Swelling Associated With HAE - (DGNews)
    FDA Approves Bepotastine Besilate Solution for Ocular Itching Associated With Allergies - (DGNews)
    FDA Approves Levocetirizine Dihydrochloride for Paediatric Nasal Allergies - (DGNews)

    News archive

     Recent webcasts/CME - Allergy Other
    • Alpha1-Antitrypsin Deficiency: Incidence, Screening, and Management
    • Early Detection of Alpha1-Antitrypsin (AAT) Deficiency Helps Prevent Disease Progression
    • Advances in Hereditary Angioedema Treatment: Considerations, Criteria & the New Therapy Options for Treatment & Prevention of HAE Attacks
      Sublingual Immunotherapy (SLIT) for Allergic Rhinitis The Latest Evidence
      Update in Hereditary Angioedema: A Disease in Rapid Evolution

      Webcasts/CME archive

       Recent cases - Allergy Other
        Gallbladder Edema in Type 1 Diabetic Patient due to Delayed-type Insulin Allergy
        Anaphylaxis Following Intravenous Fluorescein Angiography in a Vitreoretinal Clinic: Report of 4 Cases
        Acute Allergic Reaction due to Milk Proteins Contaminating Lactose Added to Corticosteroid for Injection
        Acute Generalized Exanthematous Pustulosis (AGEP) Triggered by a Spider Bite
        Anaphylactic Reaction to Camomile Tea

        Cases archive
          




        my personal edition > allergy other > news
        divider

          E-Mail this DGDispatch to a colleague

        DGDispatch


        Ebastine Effective in Both Moderate, Severe Seasonal Allergic Rhinitis: Presented at EAACI

        By Michael Smith


        AMSTERDAM, THE NETHERLANDS -- June 14, 2004 -- Ebastine, a second-generation antihistamine, works equally well in patients with either moderate or severe seasonal allergic rhinitis (SAR) symptoms, according to new research.

        In another presentation based on the same data, the researchers also concluded that the drug works to control nasal congestion in SAR, through a mechanism that remains unclear, although probably anti-inflammatory.

        Paul H. Ratner, MD, of Sylvana Research in San Antonio, Texas, United States, presented in a poster session at the 23rd Congress of the European Academy of Allergology and Clinical Immunotherapy (EAACI) the findings of a pooled analysis of 4 randomized double-blind, placebo-controlled studies of ebastine compared to placebo.

        In total, 1365 patients with SAR were studied, although 15 were excluded from the analysis for various reasons.

        The efficacy of ebastine was measured by the change in scores for 5 rhinitis symptoms: nasal discharge, nasal congestion, nasal itching, sneezing, and total eye symptoms, which were rated before the morning dose and before bedtime.

        Each symptom was rated from 0 to 3; the combined scores were expressed as a total symptom score. At baseline, all of the patients had a total symptom score of greater than 6; a score between 6 and 11.5 was classed as moderate and a score above 11.5 was classed as severe.

        The improvement in total score was highly statistically significant in both groups, Dr. Ratner said, and the improvement started quickly and was sustained through the 4-week treatment period in all the studies.

        In the placebo groups, patients with moderate symptoms saw their scores decline by an average of 1.85. Patients with severe symptoms decreased by 3.28. By comparison, those taking ebastine with moderate symptoms saw their scores drop 3.17 and those with severe symptoms by 4.74.

        While nasal congestion is not primarily histamine-driven, there is some evidence that ebastine has anti-inflammatory as well as antihistamine properties, Dr. Ratner said. With that in mind, the researchers examined the data to see what were the effects of the drug on nasal congestion in particular.

        In the placebo groups, moderate patients saw their nasal congestion scores fall by an average of 0.4 and severe patients by 0.53. Those with moderate symptoms who were taking ebastine saw their scores drop by 0.58 and those with severe symptoms by 0.81. Both differences were highly statistically significant, Dr. Ratner reported.

        More research is needed to understand exactly how this effect occurs, he concluded, but there is some evidence from pre-clinical studies that ebastine reduces inflammatory markers.

        263 - Ebastine 20 mg is an effective treatment of seasonal allergic rhinitis (SAR), in both moderate and severe patients











        E-Mail this DGDispatch to a colleague   To print, use this version






        All contents Copyright (c) 1995-2009 Doctor's Guide Publishing Limited. All rights reserved.



        The NTK initiative. Physicians helping physicians identify Need-To-Know science
           Feedback
        Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
        Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
        1
        2
        3
        4
        5
        6
        7
        Send